Moreover, the tislelizumab immunotherapy drug binding to PD-1 on the tumor surface stimulates lymphocyte secretion, boosts the resistance to tumor cells, attenuates or even reverses T cell disability or failure, reactivates the attack and killing ability of effector T cells, and enhances tumor resistance [21]. This evidence concerns the gene PDCD1 and neoplasm.